Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HDV Insulin - Diasome Pharmaceuticals

Next Previous
Drug Profile

HDV Insulin - Diasome Pharmaceuticals

Alternative Names: HDV Humalog; HDV Insulin Lispro; HDV-I; HDV-Insulin; HDV-L; Hepatic Directed Vesicle Insulin Lispro

Latest Information Update: 23 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diasome Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 07 Jun 2026 Efficacy and adverse event data from a phase II OPTI-2 trial for Type-1 diabetes mellitus released by Diasome Pharmaceuticals
  • 19 Jan 2026 Diasome Pharmaceuticals completes enrolment in phase IIb OPTI-2 trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (Parenteral, Injection) (NCT06238778)
  • 16 Dec 2025 Diasome Pharmaceuticals completes a phase IIb OPTI-2 trial in Type-1 diabetes mellitus (Treatment experienced) in USA (Parenteral, Injection) (NCT06238778)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top